Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
The total study duration will be approximately 30 weeks, consisting of 3 weeks screening period at the site, a 26 weeks treatment period, and 3 days post treatment follow up period.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with type-2 diabetes mellitus (T2DM) for at least 3 months before the screening visit.
On diet/exercise and/or treatment with metformin (stable dose of ≥1500 mg/day or maximal tolerated dose) for at least 3 months prior to screening.
Signed informed consent.
You may not be if
At screening, participant's age \< legal age of adulthood and \>80 years.
Glycated hemoglobin at screening visit \<7.0% or \>10.0%.
Body mass index (BMI) \<25 kg/m\^2 or \>45.0 kg/m\^2.
Pregnant or lactating women.
Women of childbearing potential (WOCBP) not protected by highly-effective method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy.
Diagnosis of type 1 diabetes mellitus.
Fasting plasma glucose of \>15 mmol/L (270 mg/dL) measured by the central laboratory at screening (Visit 1), and confirmed (\>15 mmol/L \[270 mg/dL\]) by a repeat test before randomization.
Treatment with glucose-lowering agents(s) other than metformin, currently or within the 3 months prior to screening.
Previous insulin use, except for episode(s) of short-term treatment (≤15 consecutive days) for intercurrent illness or pregnancy, or use of insulin within the last 6 months.
Contraindication(s) to metformin use.
Contraindication(s) to liraglutide use.
Significant change in body weight in the 3 months before screening.
Poorly controlled hypertension (a resting systolic blood pressure (SBP) \>160 mm Hg and/or diastolic blood pressure (DBP) \>95 mm Hg at screening).
History of long QT syndrome and/or QTc more than 450 ms at screening visit.
History of pancreatitis or pancreatectomy.
History of weight loss surgery.
Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC.
Any prior exposure to drugs belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists/GLP-1 analogs.
Contraindications or known hypersensitivity reaction to glucagon.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
